1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
C.Q. Pharmaceutical Holding Co., Ltd. Class A

C.Q. Pharmaceutical Holding Co., Ltd. Class A

SSZSE:000950
5.05
CNY
-0.02
(-0.39%)
0.33EPS
21.69P/E
9.85BMarket Cap
C.Q. Pharmaceutical Holding Co., Ltd. Class A
SZSE:000950
(Shenzhen Stock Exchange)

Recent

price

5.05

P/E

ratio

21.69

div

yld

9.90%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
3.45
4.27
5.48
6.79
4.93
5.53
13.28
13.33
14.94
19.76
26.08
36.07
39.18
45.18
45.55
46.9
47.2
Revenue per Share
0.22
0.15
0.2
0.02
-0.6
-0.61
0.15
0.64
0.4
0.46
0.51
0.58
0.55
0.36
0.16
0.22
0.26
Basic EPS, GAAP
-0.83
-0.52
-0.12
-1.92
-0.98
0.09
-0.24
-0.73
-1.16
-0.36
0.15
-0.14
0.01
0.15
-0.25
0.26
- -
Free Cash Flow per Basic Share
0.12
0.24
0.31
0.25
0.38
0.4
0.16
0.07
0.07
0.16
0.38
0.71
0.54
0.75
0.63
0.5
0.5
Dividend per Share
3.95
4
4.05
4.07
3.45
2.85
9.64
3.89
4.29
4.67
5.11
5.63
6.11
6.49
6.55
6.68
6.77
Book Value per Share
3.78
3.84
3.89
3.76
2.68
2.13
8.56
3.68
3.75
4.1
4.08
4.62
5.07
5.4
5.5
5.63
5.73
Tangible Book Value per Share
602
606
607
506
602
602
1,763
1,729
1,727
1,713
1,734
1,734
1,731
1,735
1,769
1,758
1,734
Basic Weighted Avg Shares
2,078
2,589
3,323
3,437
2,969
3,326
23,416
23,045
25,803
33,844
45,220
62,521
67,829
78,397
80,562
82,447
81,857
Sales/Revenue/Turnover
6.98
6.21
5.79
0.8
-8.88
-5.72
0.76
3.32
3.66
4.14
4.21
4
3.49
3.08
2.29
2.32
2.39
Operating Margin (%)
120
88
156
222
229
367
450
293
66
78
125
313
404
397
466
476
- -
Depreciation Expense
132
91
121
10
-361
-367
264
1,106
691
788
884
1,005
952
625
283
387
456
Net Income, GAAP
14.16
17.06
13.45
27.89
- -
- -
34.9
7
12.06
15.51
16.52
18.33
21.02
24.43
27.93
22.41
20.72
Effective Tax Rate (%)
6.37
3.51
3.65
0.29
-12.18
-11.04
1.13
4.8
2.68
2.33
1.96
1.61
1.4
0.8
0.35
0.47
0.56
Profit Margin (%)
709
788
1,378
493
-188
-610
1,915
4,589
5,705
5,152
7,816
9,613
8,034
11,674
13,356
10,211
9,716
Working Capital
1,315
1,341
2,116
2,752
3,138
2,575
1,316
39
978
1,220
4,234
5,634
3,327
4,613
5,482
2,710
2,214
LT Debt
2,385
2,513
2,432
2,440
2,075
1,713
6,227
7,252
8,232
8,862
10,481
11,767
12,710
15,465
16,463
16,554
16,747
Total Equity
3.55
2.3
2.78
-0.7
- -
- -
2.49
12.69
7.25
6.75
5.5
4.59
3.55
2.11
1.1
1.35
1.44
Return on Invested Capital (%)
4.49
4.21
4.16
1.51
- -
- -
4.97
14.19
7.75
7.13
5.68
5.79
5.03
4.35
2.6
2.11
2.24
Return on Capital (%)
5.56
3.82
5.04
0.42
-16.06
-19.46
7.07
17.71
9.78
10.18
10.46
10.78
9.3
5.71
2.51
3.38
3.96
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Mar'26
ST Debt
19,270
20,371
22,935
LT Borrowings
4,109
2,425
1,911
LT Finance Leases
311
285
304
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,728
1,728
1,728
Market Capitalization
8,624
10,058
9,851

Working Capital

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Mar'26
Total Current Assets
58,745
56,952
59,317
Cash, Cash Equivalents & STI
6,295
6,684
4,892
Accounts Receivable, Net
36,847
36,054
39,975
Inventories
10,293
10,041
9,908
Total Current Liabilities
46,435
46,741
49,601
Payables & Accruals
- -
- -
- -
ST Debt
19,270
20,371
22,935
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
36.83%
9.79%
0.55%
Free Cash Flow
-20.57%
123.11%
-204.09%
Net Income, GAAP
9.11%
-8.81%
36.65%
Sales/Revenue/Turnover
74.65%
13.49%
2.34%
Total Cash Common Dividend
28.69%
12.87%
-22.01%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
19,624
20,155
19,913
20,869
80,562
2025
20,612
20,576
- -
20,236
82,447
2026
20,432
- -
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
0.08
0.03
-0.01
0.16
2025
0.07
0.09
- -
- -
0.22
2026
0.1
- -
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.15
0.2
0.14
0.16
0.63
2025
0.13
0.16
- -
0.09
0.5
2026
0.12
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
C.Q. Pharmaceutical Holding Co., Ltd. C.Q. Pharmaceutical Holding Co., Ltd. (000950.SZ), a subsidiary of Chongqing Chemical & Pharmaceutical Holding Group Company, principally engages in the wholesale and retail distribution of pharmaceutical products throughout China; it conducts research, development, production, and investment in the pharmaceutical industry, including medical devices; and provides warehousing, logistics, and supply chain value-added services. The company offers a comprehensive range of medicines, medical devices, Chinese herbal medicines, health care products, and Chinese medicine tablets; operates hospital sales, commercial wholesale, retail chains, and terminal distribution networks; and delivers auxiliary medical services such as chronic disease management, electronic prescription circulation, outpatient pharmacy management, remote diagnosis and treatment, as well as medical care products for elderly care and rehabilitation while managing medical institutions. Founded in 1999 and headquartered in Chongqing, China, with approximately 13,820 employees, C.Q. Pharmaceutical Holding Co., Ltd. serves the full pharmaceutical industry chain as a fixed-point reserve unit for drugs and medical equipment; in 2025, it joined China General Technology (Group) Holdings Co., Ltd., transitioning from a local state-owned enterprise to a central enterprise in Chongqing, and completed the acquisition of a 10% stake in Chongqing Chemical and Pharmaceutical Holdings Group Finance Co.